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Abstract
Background: The health benefits of soy isoflavones have been widely investigated; however, there
are some concerns as to whether soy isoflavones, similar to ipriflavone, a synthetic isoflavone,
cause lymphocytopenia in postmenopausal women. Hence, the purpose of this study was to
investigate the extent to which 12-month supplementation of 25 g soy protein containing 60 mg
isoflavones alters lymphocyte counts or other hematological parameters in postmenopausal
women who were not on hormone replacement therapy.
Methods: Eighty-seven postmenopausal women were randomly assigned to receive either soy
protein or an equivalent amount of control protein devoid of isoflavones. Fasting venous blood was
collected at baseline and at the end of twelve month study period for complete blood count
analyses.
Results: Between the two treatment groups, the percent changes in hematological parameters,
including lymphocytes, were not different. While women consuming the soy supplement had an
increase in mean corpuscular hemoglobin concentration (MCHC) and red cell distribution width
index (RDW; a marker of reticulocytes), women consuming the control diet had higher percentage
of only MCHC.
Conclusion: Overall, the results of the present study indicate that consumption of 25 g soy
protein containing 60 mg isoflavones daily for one year does not cause lymphocytopenia.
Background
Soy protein has been reported to have positive effects on
cardiovascular [1-3] and skeletal health [4-7] in postmen-
opausal women. These health benefits of soy can be, in
part, attributed to its isoflavone content. For example,
genistein, the major isoflavone in soy, has been shown to
improve cardiovascular health by modulating lipid pro-
file and improving endothelial function in postmenopau-
sal women [1-3]. In terms of effects on bone, one-year
supplementation of the isolated isoflavone, genistein, has
been reported to significantly enhance bone mineral den-
sity of femur and lumbar spine in early postmenopausal
Published: 11 April 2006
Nutrition Journal 2006, 5:12 doi:10.1186/1475-2891-5-12
Received: 10 November 2005
Accepted: 11 April 2006
This article is available from: http://www.nutritionj.com/content/5/1/12
© 2006 Soung et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Nutrition Journal 2006, 5:12 http://www.nutritionj.com/content/5/1/12
Page 2 of 6
(page number not for citation purposes)
women in comparison to the placebo groups [7]. These
favorable effects of genistein on skeletal health have been
credited to its bone forming ability [7] while at the same
time inhibiting bone resorption [6,7]. However, to date,
the effects of soy and its isoflavones in preventing bone
loss in postmenopausal women remain inconclusive. The
findings of animal and clinical findings have ranged from
no significant changes [4,5,8-12] to a slight increase [4,13-
15] in BMD.
Despite the reported health benefits of soy isoflavones,
there are some safety concerns about their long-term use
[16,17]. These arose as a consequence of findings from a
multicenter study [16] which indicated that 13.2% of 234
postmenopausal women who received 600 mg iprifla-
vone, a synthetic isoflavone, daily for three years devel-
oped subclinical lymphocytopenia (<0.5 × 103/mm3).
Similarly, Agnusdei and Bufalino [17] observed that
approximately 3% of their subjects had lymphocyte num-
bers that fell outside the normal range after taking iprifla-
vone for two years. Ipriflavone, 7-isopropoxy-3-phenyl-
4H-1-benzopyran-4-one, is a synthetic isoflavone whose
metabolites include daidzein, a soy isoflavones; hence it is
plausible that soy isoflavones may also have negative
effects on hematological parameters including lym-
phocyte numbers. In contrast, findings from our rat study
[18] indicated that isoflavones restored the ovariectomy-
induced increase in lymphocytes and other hematological
parameters to normal levels. Therefore, the purpose of
this study was to examine the effects of a one-year supple-
mentation of 25 g soy protein containing 60 mg isofla-
vones on hematological parameters including
lymphocytes in postmenopausal women.
Methods
Study participants and design
This study was part of a one-year clinical trial examining
whether 25 g soy protein supplementation had beneficial
effects on bone mineral content and density of postmen-
opausal women [19]. In this part of the study, we report
the effects of 25 g soy protein supplementation on hema-
tological parameters including lymphocytes. Details
about the study participants, design, anthropometric
measurements, and dietary assessments were previously
described [19]. The protocol was approved by the Institu-
tional Review Board at Oklahoma State University.
Briefly, postmenopausal women 65 years of age or
younger, not on hormone replacement therapy (HRT),
were recruited for this study. Women with any bone-
related prescription medications or herbal supplements
(i.e., soy isoflavones) and with disorders such as cancer,
hypo- or hyperthyroidism, liver- or gastrointestinal- dis-
eases, insulin-dependent diabetes mellitus, pelvic inflam-
matory disease, and endometrial polyps were excluded.
A complete medical history was obtained at the beginning
of the study for each subject and one-week food frequency
questionnaires and physical activity were completed via
interview by a registered dietitian at the beginning and at
the end of the treatment period. Eighty seven qualified
volunteers were randomly assigned to receive 25 g of
either control or soy protein daily for a period of one year.
The soy protein foods provided 60 mg of isoflavones daily
in the form of snack bars, drink mixes, and cereal (DrSoy
Nutrition; Irvine, CA). The control foods were devoid of
soy isoflavones and consisted of a peanut protein-based
snack bar, a milk protein-based drink mix, and a wheat
protein-based cereal. In order to monitor compliance,
subjects were asked to return any unused supplement and
record their intake on a study calendar.
Blood collection and assessment of hematological 
parameters
Overnight fasting venous blood was collected in vacu-
tainer tubes with EDTA as an anti-coagulant (Fisher Scien-
tific) at the beginning and end of the study. Samples were
analyzed for white blood cells (WBC), percentage and
actual number of differential WBC, i.e., lymphocytes
(LYM), monocytes (MON), neutrophils (NEU), eosi-
nophils (EOS), basophils (BAS), red blood cells (RBC),
hemoglobin (Hb), hematocrit (Hct), mean corpuscular
volume (MCV), mean corpuscular hemoglobin (MCH),
mean corpuscular hemoglobin concentration (MCHC),
red cell distribution width index (RDW), platelet count
(PLT), mean platelet volume (MPV), plateletcrit (PCT)
and platelet distribution width (PDW) by an automated
combined impedance-light focusing hematology counter
(Pentra 120 Retic Hematology Instrument, ABX Diagnos-
Table 1: Subject characteristics at baseline and after one year of supplementation with soy and control foods
Measures Control (n = 27) Soy (n = 35)
Baseline Final Change (%) Baseline Final Change (%)
Age (yrs) 56.1 ± 1.1 53.3 ± 0.9
Years since 
menopause
6.43 ± 1.09 5.00 ± 0.98
BMI (kg/m2) 27.3 ± 1.0 28.2 ± 1.0 + 3.33 28.6 ± 0.9 29.0 ± 0.9 + 1.61
Data represent least square mean ± SE.
BMI = body mass index.Nutrition Journal 2006, 5:12 http://www.nutritionj.com/content/5/1/12
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tics, Irvine, CA). The intra- and inter- assay coefficient of
variations (CV) are 5.2 and 6.4%, 1.8 and 2.9%, 1.8 and
2.8%, 2.1 and 2.9%, and 6.6 and 7.8% for WBC, RBC, Hb,
Hct, and PLT, respectiviely.
Statistical analyses
Analysis of variance method was used to analyze the data
with PROC GLM in PC SAS (Version 9.1, SAS Institute,
Cary, NC). Fisher's Protected Least Significant Difference
Procedure was used to determine which means were sig-
nificantly different (P < 0.05). Data are reported as least
square mean ± standard error (SE).
Results
Subject characteristics are presented in Table 1. Of the 87
women recruited, only 62 completed the study. The
number of subjects that dropped out of the study was sim-
ilar between the two groups, 31% and 27% for the control
and soy group, respectively (Table 2).
In order to assess treatment effects, comparisons were
made between final and baseline values for hematological
parameters in each treatment group. There were no signif-
icant differences between the control and soy groups in
any of the hematological parameters when values were
expressed as percent change from baseline (Table 3, 4, 5).
However, there were differences in some of the hemato-
logical parameters when comparing baseline versus final
values. Both soy and control supplements significantly
increased the absolute number and distribution of
basophils (Table 3). Although the increase in absolute
number and distribution of basophiles were significant, it
is hard to interpret these findings as automated basophile
counts have high CVs. Only soy supplementation some-
what (P < 0.087) lowered the percentage of monocytes
(Table 3). Soy supplementation was also able to signifi-
cantly increase MCHC and RDW, but women who
received the control regimen had only higher MCHC
Table 2: Reasons for dropping out of the study
Reason Number of Subjects
Control Soy
Medical conditions preventing continuation in 
the study
12
Starting hormone replacement therapy 3 1
Non compliance with study protocol 2
Dislike of the volume or flavor of the food 3
Gastrointestinal side effects 2
Food was causing headaches 1
Personal reasons 2 3
No particular reason for dropping out of study 5
Total dropouts 12 13
Data represent least square mean ± SE. BMI = body mass index.
Table 3: Effect of one year supplementation of soy or control foods on total and the distribution of white blood cells
Measures Control (n = 27) Soy (n = 35)
Baseline Final Change (%) Baseline Final Change (%)
WBC (×103/mm3) 5.74 ± 0.32 5.78 ± 0.32 + 1.47 5.54 ± 0.28 5.74 ± 0.29 + 4.05
LYM (×103/mm3) 1.83 ± 0.09 1.79 ± 0.09 +0.47 1.81 ± 0.08 1.80 ± 0.08 +0.99
LYM (%) 32.5 ± 1.6 32.3 ± 1.6 -0.47 33.8 ± 1.4 33.1 ± 1.4 -0.62
MON (×103/mm3) 0.489 ± 0.035 0.493 ± 0.036 +5.39 0.535 ± 0.031 0.496 ± 0.032 -2.81
MON (%) 8.61 ± 0.46 8.68 ± 0.48 +3.80 9.76 ± 0.41 8.63 ± 0.42 -6.19
NEU (×103/mm3) 3.12 ± 0.25 3.15 ± 0.26 +0.96 2.91 ± 0.23 3.10 ± 0.23 +9.55
NEU (%) 53.7 ± 1.8 52.8 ± 1.8 -1.43 51.3 ± 1.6 52.2 ± 1.6 +3.54
EOS (×103/mm3) 0.176 ± 0.022 0.190 ± 0.022 +14.4 0.186 ± 0.020 0.174 ± 0.020 +4.11
EOS (%) 3.12 ± 0.33 3.34 ± 0.34 +11.3 3.31 ± 0.29 3.07 ± 0.30 +0.97
BAS (×103/mm3) 0.118 ± 0.012 0.157 ± 0.013† +53.8 0.101 ± 0.011 0.158 ± 0.011† +103
BAS (%) 2.11 ± 0.25 2.96 ± 0.26† +62.7 1.89 ± 0.22 2.95 ± 0.23† +95.6
Data represent least square mean ± SE.
† signifies that final values were significantly different (P < 0.05) from their baseline values. No differences were observed between the soy and 
control groups when parameters where expressed as change (%) from baseline.
WBC = white blood cells; LYM = lymphocytes; MON = monocytes; NEU = neutrophils; EOS = eosinophils; BAS = basophils.Nutrition Journal 2006, 5:12 http://www.nutritionj.com/content/5/1/12
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(Table 4). No changes were observed in any of the platelet
parameters as a result of dietary treatment (Table 5).
Discussion
Previous studies [20,21] indicate that estrogen deficiency
results in alterations in hematological parameters. For
example, Ben-Hur et al. [20] reported that postmenopau-
sal women between the ages of 50 to 60 years had higher
monocyte counts than women between 18 to 24 years of
age. On the other hand, women, five years or more post-
menopausal, have been reported to have lower lym-
phocyte numbers than both early postmenopausal (6
months to 2 years) and premenopausal women [21].
Hence, the present study was designed to examine
whether daily consumption of 25 g soy protein, rich in
isoflavones, by postmenopausal women for one year
affected these parameters. We hypothesized that moderate
intake of soy products containing isoflavones by post-
menopausal women may positively modulate monocyte
and lymphocyte counts. This hypothesis was based on the
earlier findings by our group [18] and others [22] showing
that isoflavones restored total and differential white
blood cell counts to normal levels in ovarian hormone
deficient rodent models. Whether such a positive effects of
soy isoflavones on hematological parameters observed in
rodent models [18,22] of ovarian hormone deficiency can
be seen in postmenopausal women needed investigation.
Although we observed that soy normalized the differential
white blood cell counts in our rat study [18], the findings
of the present clinical study indicated that consumption
of 25 g soy protein containing 60 mg isoflavones for one
year had no effect on total and differential white blood
cell counts in postmenopausal women. The differences in
response to soy isoflavone supplementation between our
human and rat studies may be due to the fact that the
hematopoietic system in humans and rodents are affected
differently in estrogen deficiency. Additionally, the
ingested levels of isoflavone per kg body weight were con-
siderably different between the two studies. The rats were
fed a diet that delivered 25 mg isoflavone per kg body
weight, whereas the postmenopausal women in our study
received the equivalent of approximately 1.1 mg isofla-
vones/kg body weight.
In terms of monocytes, increased number of monocytes
[20] has been observed when a woman reaches the age of
menopause. Moreover, monocytes from postmenopausal
women appear to be more susceptible to inflammation
than premenopausal women as shown by higher levels of
tumor necrosis factor (TNF)-α [23]. In the present study,
Table 4: Effect of one year supplementation of soy or control foods on red blood cells and related parameters
Measures Control (n = 27) Soy (n = 35)
Baseline Final Change (%) Baseline Final Change (%)
RBC (×106/mm3) 4.73 ± 0.07 4.73 ± 0.08 -0.20 4.51 ± 0.07* 4.55 ± 0.07 + 0.98
Hb (g/dl) 13.6 ± 0.2 13.6 ± 0.2 +0.09 13.2 ± 0.2 13.5 ± 0.2 +2.91
Hct (%) 40.4 ± 0.5 39.6 ± 0.5 -1.85 39.3 ± 0.5 39.5 ± 0.5 +0.82
MCV (um3) 85.6 ± 1.1 84.4 ± 1.1 -1.36 87.2 ± 0.9 87.2 ± 1.0 -0.03
MCH (pg) 28.9 ± 0.4 29.0 ± 0.4 +0.44 29.3 ± 0.4 29.8 ± 0.4 +2.02
MCHC (g/dl) 33.7 ± 0.2 34.3 ± 0.2† +1.81 33.6 ± 0.2 34.2 ± 0.2† +2.15
RDW (%) 13.3 ± 0.2 14.0 ± 0.3 +5.76 13.3 ± 0.2 13.8 ± 0.2† +4.60
Data represent least square mean ± SE. Differences were considered significant at P value < 0.05.
*indicates that baseline values of the soy group were significantly different from the baseline values of the control group
† signifies that final values were significantly different (P < 0.05) from their baseline values. No differences were observed between the soy and 
control groups when parameters where expressed as change (%) from baseline.
RBC = red blood cell; Hb = hemoglobin; Hct = hematocrit; MCV = mean corpuscular volume; MCH = mean corpuscular hemoglobin; MCHC = 
mean corpuscular hemoglobin concentration; RDW = red cell distribution width index.
Table 5: Effect of one year supplementation of soy or control foods on platelet parameters
Measures Control (n = 27) Soy (n = 35)
Baseline Final Change (%) Baseline Final Change (%)
PLT (×103/mm3) 278 ± 11 271 ± 11 -2.07 267 ± 10 274 ± 10 +2.82
MPV (um3) 9.17 ± 0.17 9.18 ± 0.17 +0.31 9.15 ± 0.15 9.16 ± 0.15 +0.44
PCT (%) 0.254 ± 0.009 0.247 ± 0.009 -1.58 0.242 ± 0.008 0.249 ± 0.008 +3.35
PDW (%) 17.3 ± 0.5 17.5 ± 0.5 +1.44 16.7 ± 0.4 16.7 ± 0.4 +0.96
Data represent least square mean ± SE.
No differences were observed between the soy and control groups when parameters where expressed as change (%) from baseline.
PLT = platelet count; MPV = mean platelet volume; PCT = plateletcrit; PDW = platelet distribution width.Nutrition Journal 2006, 5:12 http://www.nutritionj.com/content/5/1/12
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although monocyte numbers were not altered by soy
treatment, the percentage of monocytes tended (P  <
0.087) to decrease when compared with their correspond-
ing baseline values. However, this was not the case in the
group that received the control regimen. This effect of soy
isoflavones on monocytes may be similar to that of HRT
which has been shown to attenuate the elevation of
monocyte induced by estrogen deficiency [20]. Estrogen
has been shown to reduce the production of inflamma-
tory cytokines such as interleukin (IL)-1β, IL-6 and TNF-α
in postmenopausal women [24]. Therefore, it is reasona-
ble to speculate that similar to estrogen, soy isoflavones,
which are considered natural selective estrogen receptor
modulators (SERMs), may also reduce the synthesis of
inflammatory molecules in ovarian hormone deficiency.
As for the effects of isoflavones on lymphocyte counts,
reports [16,17] point to an undesirable lowering of lym-
phocytes after long-term isoflavone use. For instance,
Alexandersen et al. [16] had reported that a number of
women developed lymphocytopenia after daily intake of
600 mg ipriflavone for three years. In the present study,
we did not observe changes in lymphocyte counts in post-
menopausal women who consumed soy products deliver-
ing 60 mg isoflavones daily for one year. However,
women in the present study received one tenth of the dose
of isoflavones consumed by participants in the study by
Alexandersen and colleagues [16]. We chose the lower
dose because of its appropriateness for examining the
effects of soy on bone [6,7], which was the focus of the
current study. By comparison, the high doses of iprifla-
vone that raised concerns related to lymphocytopenia
may be considered a pharmacological dose, which is not
likely to be achieved with dietary soy supplementation.
Red cell distribution width index (RDW) and MCHC were
elevated in soy group and control group had higher levels
of only MCHC. The increase in MCHC, the ratio of hemo-
globin to hematocrit, may be due to a numerical increase
in hemoglobin concentration in the soy group and a
numerical lower hematocrit value in the control group.
Elevated RDW is associated with increased immature RBC
or reticulocyte numbers [24]. Reticulocyte counts increase
in pathological conditions such as anemia [24]. However,
this should not be the case in the present study because
values for both hemoglobin and MCHC were within nor-
mal ranges in the soy group. The observed increases in the
mean basophil counts and percent in this study were not
expected. The absolute basophil counts in both groups
slightly exceeded the reference range of 0 to 0.15 (×103/
mm3) for healthy postmenopausal women [25]. How-
ever, there were no differences in percentage changes of
basophil between soy and control groups and the women
did not report any allergic reactions therefore, it can be
concluded that the change in basophil counts observed
with soy protein was not a consequence of an allergic reac-
tion. Moreover, the changes in basophile counts may be
associated with the high coefficient of variation associated
with automated hematology analyzer. Whether the find-
ings of this one year study on hematological parameters
can also be extrapolated to isolated soy isoflavones need
further evaluation.
Conclusion
In summary, our findings suggest that soy protein with 60
mg its isoflavones does not significantly alter hematolog-
ical parameters in postmenopausal women. However, it is
necessary to further explore the impact, if any, of the
changes in monocytes, basophils and reticulocytes
observed with protein supplementation in this study.
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